Checkpoint inhibitor pneumonitis (CIP) is an immunerelated adverse event that can occur after initiation of anti-programmed death 1/programmed death ligand 1 immune checkpoint inhibitor (ICI) therapy for the treatment of multiple malignancies, including NSCLC. However, the incidence of CIP has not been previously examined in a population that included both trial-enrolled and non-trialenrolled patients with advanced NSCLC. Furthermore, risk factors and other clinical characteristics associated with CIP severity are not known. In this study, we retrospectively examined clinical characteristics, incidence, and risk factors for CIP in a cohort of 205 patients with NSCLC, all of whom received anti-programmed death 1/programmed death ligand 1 ICIs. Our results demonstrate a higher incidence of CIP (19%) than previously reported in clinical trials (3%-5%). Our data also suggest that tumor histologic type may be a risk factor for CIP development. We observed a wide range of time to onset of CIP (median 82 days), with high morbidity and mortality associated with higher-grade CIP regardless of degree of immunosuppression. Our data provide new insight into the epidemiology and clinical *Corresponding author.
Introduction
Advanced NSCLC is a malignancy with poor prognosis and typically low 1-and 5-year survival rates.
1,2 Despite use of platinum-and paclitaxel-based chemotherapeutic agents and the recent addition of biologics such as vascular endothelial growth factor inhibitors (bevacizumab and ramucirumab), survival outcomes remain poor. 3 Recently, the use of immunotherapy-based treatment regimens has shown great promise in improving overall survival and progression-free survival in NSCLC. These results, along with the poor efficacy of conventional chemotherapy, have led to recent approvals of immune checkpoint inhibitors (ICIs) as first-line therapies in advanced-stage NSCLC. Use of ICIs that target regulatory pathways, which usually suppress antitumor killing by T cells, effectively "release the brakes" on antitumor activity. However, this unique mechanism of action also produces unique toxicities, termed immunerelated adverse events (irAEs). For instance, colitis, rash, hepatitis, thyroiditis, neuropathy, nephritis, myocarditis, and inflammatory arthritis have all been reported with ICI therapy. 4, 5 One particularly worrisome irAE is the development of pneumonitis as a result of ICI therapy, which is termed checkpoint inhibitor pneumonitis (CIP).
The incidence of CIP has been reported to be between 3% and 5% in clinical trial settings, 6, 7 but the incidence of CIP in NSCLC in real-world settings is not known. CIP is a serious complication that typically presents with cough, dyspnea, and hypoxia along with pulmonary infiltrates on chest imaging (as illustrated in Fig. 1 ). CIP is typically responsive to corticosteroid therapy; however, in selected cases, patients may experience development of significant dyspnea and/or need for supplemental oxygen (i.e., Common Toxicity Criteria for Adverse Events [CTCAE] grade 3 or higher [see Supplementary Table 1] ), discontinuation of ICI therapy, and possibly initiation of additional immunosuppressives. As described recently by Naidoo et al., though rare, high-grade CIP is associated with very high morbidity and mortality. 8 Despite this, little is known about the risk factors for CIP and whether incidence differs across patient subgroups. To answer these and other fundamental questions regarding the epidemiology and pathobiology of CIP, we (as part of an irAE initiative) conducted a retrospective study of patients with NSCLC who were receiving ICI in order to better understand factors that may contribute to CIP in this at-risk patient population.
Methods

Study Population
We performed a retrospective study to determine the frequency of CIP and risk factors for its development in patients with advanced NSCLC who were treated with anti-programmed death 1/programmed death ligand 1 ICIs at Johns Hopkins Hospital between 2007 to 2017. All patients received anti-programmed death 1/programmed death ligand 1 ICI therapy either as standard of care treatment or part of a clinical trial. All patients, including those in whom ICI therapy was discontinued (because of development of CIP or for other reasons) were followed over time from the time of initiation of ICI therapy. Follow-up included an inpatient visit or phone call by a member of the research team. Date of last follow-up was identified as either the date of death, last in-person patient visit, or last research phone call. Patients who began undergoing ICI therapy before July 2017 were included in the database. An earlier version of this database was used in a prior report by our group in examining relationships between radiation and pneumonitis outcomes. 9 Onset of CIP was defined as either early (<6 months from initiation of ICI therapy) or late (>6 months after initiation of therapy).
Data Collection
Patient demographics, tumor histologic type, chemotherapy regimen, and outcomes were collected by abstraction from electronic medical records. ICI agent(s) and the presence or absence of combination ICI therapy (for example, concurrent treatment with one of more checkpoint inhibitors) and use of prior chemotherapy was collected. Quantification of radiographic characteristics was performed by a thoracic radiologist (C. T. L.). The database was then locked for addition of new patients (July 2017), and vital status (alive or dead) for these patients was updated through December 2017. The median follow-up for patients was 240 days (range 0-2415 days)
Outcome Definition
The diagnosis of CIP was determined by the treating oncologist (P. F., D. E., K. M., R. K., C. H., B. L., J. F., J. B., or J. N.) and confirmed by a multidisciplinary irAE team consisting of a pulmonologist (S. D. or K. S.), radiologist (C. L.) and a second oncologist (J. N.). Patients with SCLC, confirmed infection, progression of tumor (per the Response Criteria in Solid Tumors criteria), heart failure, or other alternative etiologies were excluded. Specifically, infection was excluded in patients with either (1) bronchoalveolar lavage culture when possible and/or (2) sputum culture and clinical determination of likelihood of infection on the basis of white blood cell count, fever, history, and examination. Furthermore, a diagnosis of CIP was held if clear evidence of tumor progression (based on either radiography, sputum or bronchoalveolar lavage, results of cytopathologic testing, or evidence of cancer spread elsewhere) was noted. For patients who experienced development of CIP, date of CIP diagnosis, maximum CIP grade (as defined by the CTCAE, version 4.0), and clinical outcome of pneumonitis management were also recorded. Improvement was defined as a decrease in oxygen requirement, increase in exercise capacity, or improvement in radiographic infiltrates after commencement of CIP treatment. Conversely, worsening was defined as lack of improvement in oxygen requirement and exercise capacity after 72 hours of steroid therapy.
Statistical Analysis
Demographic and clinical characteristics of patients who experienced development of CIP were compared with those who did not experience development of CIP by using Student's t test for continuous variables (age) or the chi-square test (categorical variables). Overall and subgroup-specific CIP incidence rates (IRs) were estimated as the number of observed CIP events divided by the person-time follow-up in years. Person-time was taken as the time from diagnosis to administrative censoring for those who did not experience development of CIP and the time from initiation of ICI therapy to diagnosis of CIP among those who experienced development of CIP. Comparison among the characteristics are reported as IR ratios (IRRs) with corresponding 95% confidence intervals (CIs). To determine whether CIP IRs differed by tumor stage, we repeated the previously described analyses while stratifying by ICI therapy (monotherapy versus combination ICI), smoking status (current/former smoker versus never-smoker and pack-years), presence or absence of antecedent chemotherapy, or tumor histologic type.
Risk factors for time to development of pneumonitis and univariate survival analysis were modeled by using a Cox proportional hazards model. Proportionality assumption and outlier testing for this model were performed, respectively, by (1) visual inspection of Schoenfeld residuals followed by chi-square testing of Cox regression model fit and (2) examination of deviance residuals. Risk of CIP at fixed time points was modeled by using logistic regression. All analyses were performed using the R software (R Foundation for Statistical Computing, Vienna, Austria) statistical environment 10 and Stata software (version 14, StataCorp, College Station, TX). 
Results
A total of 205 patients with advanced NSCLC were identified, of whom 39 (19%) experienced development CIP during follow-up. Demographic characteristics were similar between patients who did and did not experienced development of CIP (Table 1) . However, the distribution of tumor types among the patients with and without CIP was significantly different; although adenocarcinoma was the predominant NSCLC tumor type in both groups, squamous cell carcinoma comprised a larger proportion of the patients with nonadenocarcinoma) in the group with CIP (p < 0.05). Though not significant (p ¼ 0.07), the number of patients receiving pembrolizumab was lower in the group with CIP. Approximately 40% of patients were not enrolled in any clinical trials, whereas the remaining 60% of patients were enrolled in various ICI trials.
The median time to pneumonitis development was 82 days (interquartile range 20-183 days [ Supplementary  Fig. 1 and Supplementary Table 2] ). The cumulative incidence of CIP, by grade, is shown in Figure 2 . Although most pneumonitis tended to occur early (i.e., <6 months after initiation of ICI treatment) irrespective of grade, 81% of cases of CIP occurring more than 6 months after initiation of therapy (9 of 11) were grade 2 or 3. The cases of high-grade CIP (CTCAE grade 3) occurred earlier than lower-grade CIP did; however, the number of high-grade CIP cases was small (n ¼ 7).
CIP IRs and IRRs within demographic subgroups are presented in Figures 3 and 4 a Other includes large cell neuroendocrine carcinoma (2), mesothelioma (2), atypical carcinoid (2), and sarcomatoid carcinoma (1). CIP, checkpoint inhibitor pneumonitis; IQR, interquartile range; CTLA4, cytotoxic T-lymphocyte associated protein 4; ICI, immune checkpoint inhibitor.
Differences in CIP IR based on type of ICI therapy (monotherapy versus combination ICI), tumor stage, and presence or absence of antecedent chemotherapy were also examined. CIP IR was higher in individuals receiving combination therapy than in those receiving ICI monotherapy for all tumor stages ( Supplementary Figs. 2-4) .
To determine whether any temporal patterns were present with regard to the time of year during which CIP cases were diagnosed, we determined the number of cases of CIP cases diagnosed per month in our cohort. Interestingly, a higher number of CIP cases were noted in the winter (November-March [ Supplementary Fig. 5]) , with a peak of six cases in March and a nadir of one case in August.
Because radiographic patterns of CIP can be varied, we examined the patterns of infiltrates noted in computed tomography scans of patients with CIP. As shown in Figure 5 , ground glass infiltrates, consolidation, septal thickening, and traction bronchiectasis were observed. Notably, only five of 39 patients presented with pure ground glass infiltrates, and only eight of 39 patients were noted to have a purely consolidative pattern. Infiltrates were peritumoral in 14% of patients.
The results of unadjusted logistic regression evaluating risk factors for development of pneumonitis at 1 year are presented in Table 2 . Interestingly, similar to the incidence data, NSCLC of the adenocarcinoma histologic type was associated with 55% (95% CI: 0.19-0.89) lower odds of development of pneumonitis at 12 months than was NSCLC of the squamous histologic type. This relationship remained significant after adjustment for receipt of prior chemotherapy and combination ICI therapy. The results for development of CIP at 2 years were similar (data not presented).
Finally, we examined the grade and outcomes in patients in whom CIP had been diagnosed. As shown in Table 3 , CIP of grade 2 or lower occurred in approximately 35% of patients whereas grade 3 or 4 CIP was observed in 48% of cases and grade 5 CIP was observed in 5%. All patients with CIP received high-dose steroids (at least 1 mg/kg of prednisone) as per the current recommended guidelines. 11 In all, 56% of the patients with CIP (22 of 39) had their CIP improve or completely resolve with first-line steroid therapy. Among the 17 patients who did not improve with steroid therapy, CIP was noted to be stable or unchanged in five. Pneumonitis worsened after first-line therapy in nine patients (Table 4) , and the outcome was unknown in three patients.
We examined, in closer detail, the clinical characteristics of the 14 patients with CIP whose disease either did not improve or worsened after steroid treatment (see Table 4 ). The time to CIP onset was fewer than 200 days for 10 of the 14 patients. Three patients received combination ICI therapy. Only two patients whose disease worsened had received antecedent thoracic radiation. Pulmonary function test data from before initiation of ICI therapy were available for three patients; their forced expiratory volume in the first second of expiration ranged from 1.63 to 2.65 (65%-83% predicted), and their diffusion capacity of lung for carbon monoxide level ranged from 54% to 74% predicted. On presentation, their oxygen requirement ranged from room air to 100% (ventilator). Patients received steroid doses of 60 mg of prednisone or 80 to 125 mg of methylprednisolone for 2 to 4 weeks. Arterial blood gas data were available for three of nine patients; the data revealed partial pressure of oxygen-to-fraction of inspired oxygen ratios of 88 to 171 at the time of CIP diagnosis, with an ongoing oxygen requirement despite 72 hours of steroid therapy. In light of this continued deterioration, four of the nine steroid-refractory patients received second-line immunosuppressive agents (either mycophenolate mofetil or infliximab), and three of these four patients improved clinically (two of the three patients who received infliximab improved and one patient who received mycophenolate mofetil also improved). Eight of the 14 patients had died by the end of the follow-up period.
Discussion
Our current study describes the incidence of and risk factors for development of CIP in a cohort of patients with ICI-treated NSCLC. In addition to providing CIP incidence within subgroups of patients receiving ICI, these results suggest that in NSCLC, tumor histologic type and combination ICI therapy may be risk factors associated with development of CIP. The overall incidence of CIP reported by us previously 9 and in this study (19%) is significantly higher than the pneumonitis rates reported in clinical trials. 5, 7 The higher observed incidence of CIP may be partially explained by greater awareness of this entity in the past 1 to 2 years, as well as by increased pharmacovigilance with ICI administration. Furthermore, adjudication of CIP cases by a multidisciplinary panel (which is now the standard practice at our institution) likely increased the detection rate. As ICIs have quickly transitioned to becoming first-line medications for advanced-stage NCLC and as maintenance therapy for stage III NSCLC, the burden of CIP in this population is likely to increase. In fact, because we enrolled patients over several years, we examined the yearly incidence of CIP as a proportion of total cases and found that both the total number of patients receiving ICI therapy for NSCLC and the number of patients with documented CIP have increased rapidly since 2015 (see Supplementary Fig. 1 ).
Our IR and logistic regression analyses (both unadjusted and adjusted) all suggest an association between tumor histologic type and development of CIP, with a lower risk of development of CIP in patients with the nonsquamous histologic type. For the logistic regression analyses, we chose to primarily perform univariate analyses to explore relationships between baseline characteristics and development of pneumonitis and restricted our multivariate model to a few key variables because the total number of events (n ¼ 39) was small. Consistent with our data, prior randomized controlled trials 12, 13 examining ICI use in squamous and nonsquamous NSCLC reported CIP rates of approximately six of 131 (4.5%) and seven of 287 (2.4%), respectively. However, another possibility for these findings is that tumor histologic type may serve as a marker for some other patient clinical or biologic characteristic (such as performance status or other host characteristics). Interestingly, recent trials focused on nonsquamous NSCLC have reported lower CIP rates [14] [15] [16] ; our data suggest that some of this decreased incidence may be related to related factors connected with histologic type.
Our finding of a higher (IRR ¼ 1.34; 95% CI: 0.67-2.66) CIP incidence in females is intriguing. Though not significant, this datum requires further investigation; factors intrinsic to sex variability may contribute to the pathobiology of this disease, and thus, consideration of investigation in preclinical models of ICI-treated lung cancer using male and female animals may be warranted.
Our finding of a seasonal pattern (an increased number of cases in the winter) raises several interesting possibilities regarding the relationship between ICI treatment, viral infection, and CIP. One caveat to these data is that patient travel during summer months could also have artificially decreased the number of incident cases. That said, one interesting explanation for our findings is that a seasonally occurring viral infection that is not detected by a standard viral panel may be contributing to CIP development.
Our radiographic data are largely consistent with prior reports noting a variety of radiographic patterns in CIP, ranging from organizing pneumonia to primarily ground glass or interstitial patterns. [17] [18] [19] Also in accordance with prior studies 5 is our observation of increased risk for CIP with combination ICI therapy, although the increase was not statistically significant in this cohort. Interestingly, though smoking was associated with increased CIP risk in a large retrospective cohort comprising multiple tumor types, 5 we did not observe this relationship in our data set, presumably because nonsmokers were underrepresented in our data owing to the cancer type under study. We also examined both CIP IR in current, former, and never-smokers according to tumor histologic type and did not observe any significant differences, nor did we note any baseline differences in numbers of patients in each smoking classification based on tumor histologic type (data not shown).
We hypothesized that chemotherapy may increase CIP incidence; however, the rate of CIP was not significantly different in patients who had received antecedent chemotherapy than in chemonaive patients. In contrast, we observed an inverse relationship between cancer stage and CIP incidence in patients who received combination ICI therapy (i.e., a higher rate of CIP at a lower cancer stage in patients receiving combination ICI therapy). This is an intriguing finding, suggesting that earlierstage tumors, perhaps owing to differential effects on the lung inflammatory milieu, may contribute more toward "priming" the lung for CIP after ICI treatment.
Our time-to-onset analysis and case series of patients with refractory CIP suggest that there may be two different phenotypes of disease: early-onset CIP, which is characterized by high grade and early mortality, and late-onset CIP, which is predominantly of lower grade. There may be important implications for patients who have had good tumor response to ICI treatment, in whom low-grade CIP is diagnosed several months (or years) into therapy. Though we observed a mortality of 57% (eight of 14 patients) in steroid-unresponsive/ steroid-refractory CIP cases, further work is needed to determine whether CIP specifically contributed to increased mortality in this subgroup.
As discussed earlier, our data were collected over a period of 10 years during which the use of ICI in NSCLC steadily increased. To our knowledge, outside of metaanalyses, this is the largest study reporting patient-level data on CIP cases in NSCLC. Grade 1 CIP was not recorded in this data set, as these patients were by definition asymptomatic and did not undergo further evaluation for infiltrates that were noted on routine screening imaging. Demographically, certain subgroups such as Asian patients are underrepresented in this cohort. Lastly, the epidemiology and risk factors associated with CIP may continue to evolve as patients previously thought to be ICI unresponsive start receiving an ICI as part of newer chemotherapeutic strategies aimed at expanding the envelope of ICI-eligible patients with NSCLC.
In conclusion, CIP is a complication of ICI therapy that may be occurring at a higher rate than previously reported in patients with ICI-treated NSCLC. Risk factors for development of CIP, such as age, tumor histologic type, and use of combination ICI, warrant further study. Study of CIP subtypes based on time to onset and initial CIP grade may provide more insight into the biology of this very relevant disease of increasing prevalence. 
